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Abstract
In population-based cancer survival analysis, the net survival is important for government to
assess health care programs. For decades, it is observed that the net survival reaches a plateau
after long-term follow-up, this is so called “statistical cure”. Several methods were proposed
to address the statistical cure. Besides, the cure time can be used to evaluate the time period
of a health care program for a specific patient population, and it also can be helpful for a
clinician to explain the prognosis for patients, therefore the cure time is an important health
care index. However, those proposed methods assume the cure time to be infinity, thus it is
inconvenient to make inference on the cure time. In this dissertation, we define a more general
concept of statistical cure via conditional survival. Based on the newly defined statistical cure,
the cure time is well defined. We develop cure time model methodologies and show a variety of
properties through simulation. In data analysis, cure times are estimated for 22 major cancers
in Taiwan, we further use colorectal cancer data as an example to conduct statistical infer-
ence via cure time model with covariate sex, age group, and stage. This dissertation provides a
methodology to obtain cure time estimate, which can contribute to public health policy making.
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Chapter 1
Introduction
1.1 Population-based cancer survival analysis
In the recent years, data collection are going to be faster and more effective in governments
or companies. The collected data size expands rapidly in both sample size and number of
variables. Therefore, using appropriate statistical methods to extract useful knowledge from
the large databases becomes an important but challenging issue. From the perspective of
public health, population-based cancer survival analysis focuses on analyzing national cancer
databases and extracting important information, from which government is able to evaluate
health care programs.
Let D be the event time from the disease of interest. Researchers are often interested in the
behaviour of D. However, in population-based cancer survival analysis, we can not observe D
directly, instead we observe
T = min(O,D),
where O is the event time from all causes except the disease of interest. It is said that D
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considers a hypothetical situation where the cause of death is only due to the disease of interest
(Pohar-Perme et al., 2012). Statistical inference of D is thus often made under the independence
assumption
O ⊥ D, (1.1)
in which situation the distribution of D is estimable. Based on (1.1), the involved survival
functions and the corresponding hazard functions can be expressed as
ST (t) = SO(t)SD(t)⇐⇒ hT (t) = hO(t) + hD(t), (1.2)
where ST (t) = P (T > t), SO(t) = P (O > t) is the disease-free survival, and SD(t) = P (D > t)
is the net survival, and hT (t), hO(t), and hD(t) are the hazard functions of T , O, and D,
respectively.
Under (1.1), the idea of relative survival can be used to estimate SD(t) non-parametrically
by
RS(t) =
ŜT (t)
SO(t)
,
where ŜT (t) is an estimate of ST (t) (e.g. the Kaplan-Meier estimator), and SO(t) can be
obtained from national death certificate database. There are different kinds of relative survival
estimates, depending on the method used to calculate SO(t) (Ederer et al., 1961; Hakulinen,
1982).
1.2 Statistical cure and cure rate model
In decades, more and more complex diseases are said to be curable (Castillo et al., 2013). One
can also observe the cure phenomenon from a diseased population after long-term follow-up,
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that is “SD(t) reaches a plateau pi after long-term follow-up”, which can be formulated as
lim
t→∞
SD(t) = pi. (1.3)
It also implies from the relation (1.2) that the excess hazard hD(t) decreases to 0 as t goes to
infinity. In this situation, patients will no longer die from the disease of interest, which is called
“population cure” or “statistical cure” (Dubecz et al., 2012). The constant pi in (1.3) represents
the proportion of patients that will no longer die from the disease of interest, which is called
the cure rate. Notice that the concept of “cure” can be interpreted in individual level and
population level. In the individual level, the cure can be thought of as “medical cure”, which
means asymptomatic of an individual after receiving medical treatment. In the population
level, “population cure” or “statistical cure” occurs when the excess hazard decreases to zero
(Lambert et al., 2007). In order to characterize the information of cure, we often use the cure
rate model (or cure fraction model) to estimate the cure rate pi.
Cure rate model has been well developed in these decades, and we can simply classify the
models into mixture cure rate model (De Angelis et al., 1999) and non-mixture cure rate model
(Andersson et al., 2011). The mixture cure rate model considers the mixture distribution of
cure and uncure for each patient. Let the cure condition R ∼ Bernoulli(pi). If a patient will be
cured, then R = 1, otherwise R = 0. Then, with conditions in Lemma 1, it can be shown that
SD(t) is of the form
ST (t) = SO(t){pi + (1− pi)Su(t)}, (1.4)
where Su(t) = P (D > t|R = 0) is the survival of uncured patients, and pi = P (R = 1) is the
cure rate.
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Lemma 1. The following conditions implies (1.4).
(a) O ⊥ (D,R),
(b) D =∞ if R = 1.
Another method, the non-mixture cure rate model, derives ST (t) from a different perspec-
tive. Let N be the number of metastatic-competent cancer cell number for each patient after
treatment, and let F0(t) be the cdf of the event time with a metastatic-competent cancer
cell. The non-mixture cure rate model assumes that N ∼ Poisson(λ), then it is straightfor-
ward that those patients without metastatic-competent cancer cell are considered cured, i.e.
pi = P (N = 0) = e−λ is the cure rate. With conditions in Lemma 2, it can be shown that SD(t)
is of the form
ST (t) = SO(t)pi
F0(t). (1.5)
Lemma 2. The following conditions implies (1.5).
(a) D|N = min(D1, D2, . . . , DN),
(b) D1, . . . , DN
iid∼ F0(t),
(c) O ⊥ (D,N),
(d) D =∞ if N = 0,
where Di denotes the event time from the i-th metastatic-competent cancer cell.
Note that (1.5) can also be represented as the form of mixture cure rate model
SO(t)pi
F0(t) = SO(t)
{
pi + (1− pi)pi
F0(t) − pi
1− pi
}
,
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where pi
F0(t)−pi
1−pi is a proper survival function, and can be used to model Su(t).
Under appropriate modelling of Su(t) for (1.4), or F0(t) for (1.5), one can estimate pi via
MLE inference procedure. Recently, the flexible parametric cure rate model (Andersson et al.,
2011), which uses the restricted cubic spline function to model F0(t), is considered to be a
suitable method in describing cure in a variety of cancers.
Compare with (1.2), the above model is equivalent to model the net survival SD(t)
SD(t) = pi + (1− pi)Su(t)
in the mixture cure rate model, and as
SD(t) = pi
F0(t)
in the non-mixture cure rate model. Note that, in both types of cure rate models SD(t) are
improper survival functions, since (1.3) tells that the long-term follow-up time of SD(t) attains
pi as t goes to infinity.
1.3 Cure time
Equation (1.3) indicates that the cure rate can be attained as t tends to infinity. However, it
is observed that the net survival may attain the cure rate after a specific time point τ within
the follow-up time, instead of infinity. This specific time point τ is called “cure time”. The
government may want to know the cure time, so that the health policies can be conducted more
efficiently. In Taiwan, the a cancer patient will be assigned a catastrophic illness certificate,
and it should be re-evaluated after the cancer cure time. Moreover, the burden of diseases
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can be assessed more accurately if the government has a better estimate of cure time (Blakely
et al., 2010, 2012). An example is that the years lived with disability (YLD) needs a time
point to exclude those patients who live a long period so that the disability is negligible.
In pharmaceuticals, it is important to know the time when patients are identical to general
population after taking new treatment. Clinicians may be also interested in cure time for
precise health care suggestions to patients. There are na¨ıve ways to determine the cure time τ .
Some non-parametric methods were suggested in practical use, one of them suggested that the
estimated cure time occurred after 95% or 99% of the deaths had elapsed (Woods et al., 2009;
Smoll et al., 2012). The above strategy is easy to implement but may fail to apply if the true
time point occurs beyond the follow-up time, or the cure assumption (1.3) is inappropriate. It
was also suggested to use conditional relative survival to find the cure time, i.e. to find the
smallest τ such that the conditional relative survival exceeds 95% (Janssen-Heijnen et al., 2007,
2010; Dal Maso et al., 2014)
τ = min {k | RS(t|k) > 95% ∀ t ≥ k} ,
where RS(t|k) = RS(t)/RS(k) is the conditional relative survival. However, the choice of
95% is subjective, and it is possible to see a non-negligible decreasing trend of conditional
relative survival even if it exceeds 95%. Baade, Youlden, and Chambers (2011) proposed to use
conditional relative survival to determine τ visually after which RS(t|τ) is nearly a constant.
Blakely et al. (2012) suggested a convenient way by visually identify the time point of non-
declination in the model-based or non-parametric net survival curve. These methods still face
the problem that the determination of τ is subjective. Moreover, there exists no statistical
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inference procedure for τ in the above mentioned methods.
The research aim of this dissertation is to give a new perspective of statistical cure, from
which the information of cure time can be included. We also propose a parametric method
to model τ , which would be able for the researchers to make statistical inference about cure
time. In application, the proposed methodology can be used not only on the population-based
cancer survival analysis, but also on the clinical-based research, in which the diseased cohort
with certain medical treatment can be compared to the general population.
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Chapter 2
A New Perspective of Statistical Cure
with Cure time
In this chapter, we propose another concept to define “statistical cure” from which the cure time
can be directly characterized. We begin from a comparison of general population and diseased
population. One can treat the general population as a pool of normal persons with negligible risk
of death from the disease of interest. Therefore, it is obvious that normal persons are expected
to have better survival experience than diseased population, i.e. SO(t) ≥ ST (t) ∀ t > 0. Taking
the colorectal cancer population and the corresponding disease-free survival in Taiwan as an
example, Figure 2.1(a) shows that the disease-free survival SO(t) is uniformly higher than the
observed survival of colorectal cancer patient. We can also see that ST (t) decreased rapidly in
the beginning, but the decreasing trend becomes similar to SO(t) when t > 5. It implies that
patients who survived at 5 years may have similar survival experience as the general population.
It motivates us to find the cure time by comparing the conditional survival functions of the
diseased population and general population. For any time point k, the conditional survival of
8
(a) (b)
Figure 2.1: Conditional survival of colorectal cancer data and general population in Taiwan,
diagnosed between 1995 and 2013 with follow-up to 2014.
diseased population given surviving at k is defined to be
ST (t|k) = P (T > t|T > k) = ST (t)
ST (k)
∀ t ≥ k,
which can be explained as the survival probability of a person who lived upon k from the be-
ginning of follow-up (e.g., diagnosis of disease). Note that ST (t) can be expressed as ST (t|0).
Figure 2.1(b) shows two survival curves conditional on 5 years for SO(t|5) and ST (t|5). Obvi-
ously, ST (t|5) is much more close to SO(t|5), which means that those patients who has survived
at 5 years would have similar survival experience to general population. This example motivates
us to develop a new concept of “statistical cure”.
Definition 1 (Statistical Cure). The statistical cure is attained if there exists some k > 0
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such that
ST (t|k) = SO(t|k) ∀ t > k. (2.1)
The cure time τ is defined as the minimum time point satisfying statistical cure as
τ = min {k | ST (t|k) = SO(t|k) ∀ t > k} . (2.2)
Definition 1 means that those patients who have survived at τ can not be distinguished
from the general population in the sense of conditional survival. Definition 1 also provides a
connection between cure time and cure rate as summarized below.
Theorem 1. Assume condition (1.1). Then (2.1) is equivalent to
SD(t) = pi ∀ t > τ, (2.3)
where pi = SD(τ) is the cure rate, and τ is the cure time.
In (2.3), τ is used to demonstrate the time that SD(t) attains pi, while in (1.3), τ is forced
to be infinity. Thus (2.3) shows not only cure rate pi, but also cure time τ . We note that
(2.1) is the most general definition for “statistical cure”, since it does not need the assumption
(1.1), while (2.3) relies on the validity of (1.1). Note also that (2.3) is more general than the
conventional (1.3), by noting that (2.3) becomes (1.3) if τ → ∞. Figure 2.2 summarizes the
relationship between different concepts of statistical cure.
10
ST (t|τ) = SO(t|τ) ∀ t > τ
SD(t) = pi ∀ t > τ
limt→∞ SD(t) = pi
O ⊥ D
τ →∞
Figure 2.2: Relationships between different concepts of statistical cure
We close this chapter by developing some properties related to Definition 1 that can help
understand the meaning of statistical cure.
Theorem 2. Assume condition (1.1). Then, either statement (a) or (b) below is equivalent to
(2.1)
(a) T = min(O,D) · I(D ≤ τ) +O · I(D > τ)
(b) hT (t) = hO(t) + hD(t) · I(t ≤ τ)
where I(.) denotes the indicator function.
From Theorem 2, under the consideration of cure, the survival function of T is derived to
be
ST (t) = SO(t)UD(t; τ), (2.4)
where
UD(t; τ) = {SD(t)− SD(τ)} · I(t ≤ τ) + SD(τ) (2.5)
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only depends on D and τ . Note that in Theorem 2(a), O and D are competing events if D ≤ τ ,
but there is only O as the event time when D > τ . It means that after τ , patient would never
die from D (i.e., τ is the cure time). Comparing Theorem 2(b) to hazard function in (1.2),
we know that hD(t) exists for all t in (1.2) without cure. However, in the presence of cure, in
some diseases the effect of hD(t) vanishes in late period of follow-up. Those who had long-term
follow-up are nearly identical to normal person, and this requirement is fulfilled by assuming
hD(t) disappears after a fixed time point τ as stated in Theorem 2(b). In the following chapters,
we would introduce a cure time model for estimating τ based on Theorem 2.
Remark 1. A special case of Theorem 2(b) is hT (t) = hD(t) · I(t ≤ τ), where O is assumed to
be infinity. A Bayesian semi-parametric approach was proposed to estimate the cure time (in
this article the cure time is called “unknown threshold”) under this special case (Nieto-Barajas
& Yin, 2008), but it was not suitable for population-based studies since the semi-parametric
model did not incorporate the information of O.
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Chapter 3
Statistical Inference Procedure of Cure
Time
3.1 Data structure
The sample is in the form of {Z, δ,X}, where Z = min(T,C) is the last observed time, C is
the censoring time, X ∈ Rp is the covariate, and δ is the censoring status. Taiwan has a well-
developed health care system, and considering the high-quality death certificate information
should be helpful to obtain more efficient statistical inference. In this study, we propose a more
general perspective to apply the cause of death information, and define a more general version
of censoring status, that is
δ =

0, if Z = C
1, if Z = O
2, if Z = D
3, if Z = T
, (3.1)
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where D is obtained based on the cause of death information. Note that O indicates the time
from all causes of death except the disease of interest, therefore the censoring should not include
any other cause of death, such as car accident.
Since covariate X has been involved in estimation, (1.1) should be modified as a relaxed
assumption. It is also reasonable to assume that C is independent of all the last observed time,
or (O,D). The assumptions used in estimation can therefore be expressed below
(C1) O ⊥ D|X
(C2) C ⊥ (O,D)|X.
In the previous population-based methodologies it was suggested using T and C to define
δ, and ignore death certificate information completely since the accuracy of death certificates
are often problematic (Howlader et al., 2010; Huang et al., 2014). However, it is reasonable for
researchers to determine whether to use the cause of death information completely or partially,
according to quality of the database from health care system of their countries. In this data
structure, δ = 3 means that we know that the last observed time is T but do not know whether
T = D or T = O, and δ = 3 often occurs in the case of uncertain cause of death from death
certificate database (Naghavi et al., 2010). Moreover, researchers can choose not to use the
information of O and D, but instead set δ = 3 for an individual if his/her cause of death
information is doubtful, or if the quality of the cause of death information is not reliable.
Therefore, we provide a flexible way of data usage to let researchers make use of data more
thoroughly.
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3.2 Model specification
According to Theorem 2(b), excess hazard hD and cure time are affected by X. Therefore, we
propose the cure time model (CTM)
hT (t|X) = hO(t) + hD(t|X(1)) · I (t ≤ τX(2)) , (3.2)
where X(1) and X(2) are subsets of X, respectively. Since the cure time τ must not be negative,
τ can be modelled using any link function with positive range, such as
τX(2) = exp(β
TX(2)),
where β is the parameter corresponding to X(2). hD(t|X(1)) is assumed to be the excess haz-
ard function from a parametric distribution. For example, the excess hazard function can be
modelled as Weibull hazard function, where the link function is set to be exponential function
for both shape and scale parameters. In population-based survival analysis, we obtain the
information of hO(t) through vital statistics from government.
3.3 Estimation
We use maximum likelihood estimation to obtain the estimate of (α, β)T , where α is the pa-
rameter of the parametric distribution to model D. If we model D as Weibull distribution, then
α = (α1, α2)
T , where α1 is used to model the shape parameter in the form of exp(α
T
1X
(1)), and
α2 is used to model the scale parameter in the form of exp(α
T
2X
(1)). Since δ contains four levels,
we can derive the likelihood function of each level through the corresponding pdf respectively.
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The case of δ = 0
For a censored case with given covariate X = x, the observation is (z, δ = 0, x), and we have
P (Z > z, δ = 0|X = x) = P (Z > z,C < T |X = x) = P (C > z,C < T |X = x)
=
∫ ∞
z
∫ ∞
c
fT (t|x)fC(c)dtdc
=
∫ ∞
z
ST (c|x)fC(c)dc,
where fC(z) is the pdf of censoring time C. The pdf of (Z, δ = 0) given covariate x is
fZ,δ|X(z, 0|x) = − d
dz
∫ ∞
z
ST (c|x)fC(c)dc
= ST (z|x)fC(z)
= UD(z; τ |x)SO(z)fC(z), (3.3)
where UD(z; τ |x) is similar to (2.5), but involving covariate x, that is
UD(z; τ |x) =
{
SD(z|x(1))− SD(τx(2)|x(1))
}
I (z ≤ τx(2)) + SD(τx(2)|x(1)). (3.4)
Equation (3.4) tells that if z ≤ τx(2) , then UD(z; τ |x) = SD(z|x(1)); if z > τx(2) , then UD(z; τ |x)
remains a constant SD(τx(2)|x(1)).
In (3.3), the censoring time C contributed to the pdf via fC(z), and we did not observe the
exact time from O and D, but O > z and D > z, therefore the pdf was contributed via SO(z)
and UD(z; τ |x), respectively. Since we assume that C, O, and D are independent of each other,
the pdf (3.3) are simply the product of UD(z; τ |x), SO(z), and fC(z).
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The case of δ = 1
For a case with the last observed time being O, the observation is (z, δ = 1, x), and we have
P (Z > z, δ = 1|X = x) =P (O > z,O < D,D ≤ τ, O < C|X = x)+
P (O > z,D > τ,O < C|X = x)
=
∫ τ
x(2)
z
∫ τ
x(2)
o
∫ ∞
o
fD(w|x)fO(o)fC(c) dc dw do+∫ ∞
z
∫ ∞
τ
x(2)
∫ ∞
o
fD(w|x)fO(o)fC(c) dc dw do
=
∫ τ
x(2)
z
{SD(o|x(1))− SD(τx(2)|x(1))}fO(o)SC(o) do+∫ ∞
z
SD(τx(2)|x(1))fO(o)SC(o) do,
where SC(.) is the survival function of C, and fO(.) is the pdf of O. The pdf of (Z, δ = 1) given
covariate x is
fZ,δ|X(z, 1|x) =− d
dz
∫ τ
x(2)
z
{SD(o|x(1))− SD(τx(2) |x(1))}fO(o)SC(o) do−
d
dz
∫ ∞
z
SD(τx(2)|x(1))fO(o)SC(o) do
={SD(z|x(1))− SD(τx(2)|x(1))}fO(z)SC(z)I(z ≤ τx(2)) + SD(τx(2) |x(1))fO(z)SC(z)
=
[{SD(z|x(1))− SD(τx(2)|x(1))}I(z ≤ τx(2)) + SD(τx(2)|x(1))] fO(z)SC(z)
=UD(z; τ |x)fO(z)SC(z). (3.5)
In (3.5), O contributed to the pdf via fO(z), and we did not observe the exact time from C
and D, but we know that C > z and D > z, therefore the pdf was contributed via SC(z) and
UD(z; τ |x), respectively.
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The case of δ = 2
For a case with the last observed time being D, we have observation (z, δ = 2, x), and
P (Z > z, δ = 2|X = x) = P (D > z,D < O,D ≤ τ,D < C|X = x)
=
∫ τ
x(2)
z
∫ ∞
w
∫ ∞
w
fD(w|x(1))fO(o)fC(c) dc do dw
=
∫ τ
x(2)
z
fD(w|x(1))SO(w)SC(w) dw.
The pdf of (Z, δ = 2) given covariate x is
fZ,δ|X(z, 2|x) = − d
dz
∫ τ
x(2)
z
fD(w|x(1))SO(w)SC(w) dw
= fD(z|x(1))SO(z)SC(z)I(z ≤ τx(2)). (3.6)
Note that, since (z, δ = 2, x) is the event time from the disease of interest, it is an “uncured”
case, and the last observed time z is therefore smaller than the cure time τx(2) , that is z ≤ τx(2) ,
or
log(z) ≤ βTx(2). (3.7)
(3.7) should be considered as a natural constraint for any observation with δ = 2 during
estimation of β, which will be demonstrated later.
In (3.6), D contributed to the pdf via fD(z|x(1)), and we did not observe the exact time
from O and C, but only O > z and C > z, therefore the pdf was contributed via SO(z) and
SC(z), respectively.
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The case of δ = 3
For a case with the last observed time being T , the observation is (z, δ = 3, x), and
P (Z > z, δ = 3|X = x) = P (T > z, T < C|X = x)
=
∫ ∞
z
∫ ∞
t
fT (t|x)fC(c) dc dt
=
∫ ∞
z
fT (t|x)SC(t) dt.
The pdf of (Z, δ = 3) given covariate x is
fZ,δ|X(z, 3|x) = − d
dz
∫ ∞
z
fT (t|x)SC(t) dt
= fT (z|x)SC(z)
= hT (z|x)UD(z; τ |x)SO(z)SC(z). (3.8)
In (3.8), T contributed to the pdf via fT (z|x) = hT (z|x)UD(z; τ |x)SO(z), and we did not observe
the exact time from C, but only C > z, therefore the pdf was contributed via SC(z). Note that
hT (z|x) = hO(z) + hD(z|x(1)) · I(z ≤ τx(2)), the information of hO(z), which can be obtained
through the national death certificate database, must be further included in this pdf.
By incorporating the pdfs from the corresponding levels of δ, we can obtain the likelihood
function L(α, β) as summarized below
Theorem 3. Given the censored data {zi, δi, xi}ni=1, where zi and xi are the i-th last observed
time and covariate, respectively, and δi is defined as (3.1). Assume (C1) and (C2). The
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likelihood function L(α, β) under CTM is
L(α, β) =
{ ∏
i:δi=0
UD(zi; τ |xi)SO(zi)fC(zi)
}
×
{ ∏
i:δi=1
UD(zi; τ |xi)fO(zi)SC(zi)
}
×
{ ∏
i:δi=2
fD(zi|x(1)i )SO(zi)SC(zi)I(zi ≤ τx(2)i )
}
×
{ ∏
i:δi=3
hT (zi|xi)UD(zi; τ |xi)SO(zi)SC(zi)
}
.
Let (α̂, β̂)T be the estimate of (α, β)T , we obtain (α̂, β̂)T through
(α̂, β̂)T = arg max
α,β
{
l(α, β)− n
2
κβTβ
}
,
where l(α, β) = lnL(α, β), and κ ≥ 0 is the smoothing parameter to obtain more stable esti-
mation. We suggest κ to be related to the sample size n, such as κ = 1/n or κ = 1/(
√
n log n),
one can also set κ = 0 to remove the penalty effect. Eliminating those parts independent of
α, β, we obtain
l(α, β) =
∑
i:δi=0,1
logUD(zi; τ |xi) +
∑
i:δi=2
log{fD(zi|x(1)i )I(zi ≤ τx(2)i )}+
∑
i:δi=3
{log hT (zi|xi) + logUD(zi; τ |xi)} , (3.9)
Note that the censored case (δ = 0), and the case dying from any cause except the disease of
interest (δ = 1), have equally contribution to the objective function l(α, β).
3.4 Implementation
We use the gradient descent method for α estimation given fixed β, which is described in Chap-
ter 3.4.1, and use the gradient projection method to estimate β given fixed α in a modified
objective function, which is described in Chapter 3.4.2. The above two methods are imple-
mented iteratively until convergence.
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3.4.1 Estimation of α given β
When β is given, τ
x
(2)
i
is a constant, therefore the observation can be partitioned into {zi : zi ≤
τ
x
(2)
i
} and {zi : zi > τx(2)i }, the objective function (3.9) can be expressed as
lβ(α) =
∑
{i:δi=0,1; zi≤τ
x
(2)
i
}
logSD(zi|x(1)i ) +
∑
{i:δi=0,1; zi>τ
x
(2)
i
}
logSD(τx(2)i
|x(1)i )+
∑
{i:δi=2; zi≤τ
x
(2)
i
}
log fD(zi|x(1)i ) +
∑
{i:δi=3; zi≤τ
x
(2)
i
}
[
logSD(zi|x(1)i ) + log
{
hO(zi) + hD(zi|x(1)i )
}]
+
∑
{i:δi=3; zi>τ
x
(2)
i
}
{
logSD(τx(2)i
|x(1)i ) + log hO(zi)
}
with derivative
∂
∂α
lβ(α) =
∑
{i:δi=0,1; zi≤τ
x
(2)
i
}
{SD(zi|x(1)i )}−1
∂
∂α
SD(zi|x(1)i )+
∑
{i:δi=0,1; zi>τ
x
(2)
i
}
{SD(τx(2)i |x
(1)
i )}−1
∂
∂α
SD(τx(2)i
|x(1)i )+
∑
{i:δi=2; zi≤τ
x
(2)
i
}
{fD(zi|x(1)i )}−1
∂
∂α
fD(zi|x(1)i )+
∑
{i:δi=3; zi≤τ
x
(2)
i
}
[
{SD(zi|x(1)i )}−1
∂
∂α
SD(zi|x(1)i )+
{
hO(zi) + hD(zi|x(1)i )
}−1 ∂
∂α
{
hO(zi) + hD(zi|x(1)i )
}]
+
∑
{i:δi=3; zi>τ
x
(2)
i
}
{SD(τx(2)i |x
(1)
i )}−1
∂
∂α
SD(τx(2)i
|x(1)i ).
We use the gradient descent method to optimize l(α, β) given β, which is the same as optimizing
lβ(α)
α̂(β) = arg max
α
lβ(α).
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3.4.2 Estimation of β given α
As α = α̂(β) is given,
∑
δi=2
log
{
fD(zi|x(1)i )I
(
zi ≤ τx(2)i
)}
in l(α, β) implies that for i-th
observation from Di (δi = 2 if Zi = Di), the cure time τx(2)i
must be larger than Di, therefore
zi ≤ τx(2)i is naturally a linear constraint, that should be considered in the optimization of
l(α, β). Let lα(β) be l(α, β) given α, and without the information of those δi = 2
lα(β) =
∑
i:δi=0,1
logUD(zi; τ |α, xi) +
∑
i:δi=3
{log hT (zi|α, xi) + logUD(zi|α, xi)}. (3.10)
The optimization of lα(β) is equivalent to the following optimization problem
maximize lα(β)− n2κβTβ
subject to log(zi) ≤ βTx(2)i , ∀ i such that δi = 2.
Note that, in lα(β) the indicator function I(zi ≤ τx(2)i ) leads to non-differentiation at β. To deal
with this problem, Ma and Huang (2007) suggested using the sigmoid function
R(u;σn) =
{
1 + exp
(
− u
σn
)}−1
to approximate I
(
u ≥ 0), where the tuning parameter σn is a sequence of positive numbers
satisfying limn→∞ σn = 0. Note that limσn→0R(u;σn) = I
(
u ≥ 0).
Denote the modified objective function of (3.10), lα,σn(β) as
lα,σn(β) =
∑
i:δi=0,1
logUα,σn(zi; τ |xi) +
∑
i:δi=3
{
log hα,σn(zi|xi) + logUα,σn(zi|xi)
}
,
where
hα,σn(zi|xi) = hO(zi) + hD(zi|α, x(1)i )R(τx(2)i − zi;σn),
Uα,σn(zi; τ |xi) = {SD(zi|α, x(1)i )− SD(τx(2)i |α, x
(1)
i )}R(τx(2)i − zi;σn) + SD(τx(2)i |α, x
(1)
i ).
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All the indicator functions I(zi ≤ τx(2)i ) i ∈ {i|δi = 0, 1, 3} in l(α, β) are replaced by sigmoid
function R(τ
x
(2)
i
− zi;σn), thus the modified objective function lα,σn(β) is differentiable at β. In
l(α, β), those observations with δi = 2 do not contribute to lα,σn(β), but become natural linear
constraints for (α, β)T .
For a fixed α, the gradient projection method (Luenberger & Ye, 2008) is used to solve the
optimization problem
maximize lα,σn(β)− n2κβTβ
subject to log(zi) ≤ βTx(2)i , ∀ i such that δi = 2.
The derivative of lα,σn(β) is
∂
∂β
lα,σn(β) =
∂
∂β
∑
i:δi=0,1
log
[
Uα,σn(zi; τ |xi)
]
+
∂
∂β
∑
i:δi=3
{
log
[
Uα,σn(zi; τ |xi)
]
+ log
[
hα,σn(zi|xi)
]}
=
∑
i:δi=0,1
{Uα,σn(zi; τ |xi)}−1
∂
∂β
Uα,σn(zi; τ |xi)+
∑
i:δi=3
[
{Uα,σn(zi; τ |xi)}−1
∂
∂β
Uα,σn(zi; τ |xi) + {hs(zi|xi)}−1
∂
∂β
hα,σn(zi|xi)
]
,
where
∂
∂β
hα,σn(zi|xi) = hD(zi|α, x(1)i )
∂
∂β
R(τ
x
(2)
i
− zi;σn),
∂
∂β
Uα,σn(zi; τ |xi) = −
∂
∂β
SD(τx(2)i
|α, x(1)i )R(τx(2)i − zi;σn)+{
SD(zi|α, x(1)i )− SD(τx(2)i |α, x
(1)
i )
} ∂
∂β
R(τ
x
(2)
i
− zi;σn) + ∂
∂β
SD(τx(2)i
|α, x(1)i ).
We use the gradient projection method (Luenberger & Ye, 2008) to obtain the estimate of β
given α.
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3.4.3 Estimation of (α, β)T
We use an iterative algorithm below to obtain (α̂, β̂)T :
Estimation algorithm
1. Given an initial vector β̂(0), obtain the first iterative estimate of α, α̂(1), by optimizing
lβ̂(0)(α) using gradient descent.
2. Obtain the first iterative estimate of β, β̂(1), by optimizing lα̂(1),σn(β) using gradient
projection method.
3. Repeat step 1. and step 2. until obtaining (α̂, β̂)T = (α̂(∞), β̂(∞))T .
3.5 Standard error
The parametric bootstrap method is used to generate the null distribution and estimate the
standard error of (α̂, β̂)T .
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Parametric bootstrap algorithm for CTM
1. For i = 1, . . . , n, let δ
(c)
i = 1 if δi = 0, δ
(c)
i = 0 if δi 6= 0. Fit Weibull model to
{Zi, δ(c)i }ni=1 to obtain the censoring distribution estimate α̂c.
2. For b = 1, . . . , B, for i = 1, . . . , n,
(a) Generate C
(b)
i from Weibull model with parameter α̂c.
(b) Generate O
(b)
i by using vital statistics from government (in Taiwan we have the
hazard of each calendar year 1985-2017, each 0-100 years old, and each sex cat-
egory). Calculate the conditional survival Si(t|yi, ai, si) with corresponding di-
agnosed year yi, age ai, and sex si. Then draw a random sample u
(b)
i from
uniform(0, 1), and S−1i (u
(b)
i |y, a, s) is O(b)i .
(c) Generate D
(b)
i from SD(t|α̂, Xi).
(d) Calculate T
(b)
i = min(O
(b)
i , D
(b)
i ) · I(D(b)i ≤ τ̂i) + O(b)i · I(D(b)i > τ̂i), where τ̂i =
exp(β̂TXi).
(e) If C
(b)
i < T
(b)
i then δ
(b)
i = 0 and Z
(b)
i = C
(b)
i . Otherwise generate v
(b)
i from
Bernoulli
(
P̂ (Z=T )
P̂ (Z=O)+P̂ (Z=D)+P̂ (Z=T )
)
. If v
(b)
i = 1 then δ
(b)
i = 3 and Z
(b)
i = T
(b)
i . If
v
(b)
i = 0 and T
(b)
i = D
(b)
i , then δ
(b)
i = 2 and Z
(b)
i = D
(b)
i . If v
(b)
i = 0 and T
(b)
i = O
(b)
i ,
then δ
(b)
i = 1 and Z
(b)
i = O
(b)
i .
3. Obtain the bootstrapped estimate (α̂(b), β̂(b))T using {Z(b)i , δ(b)i , Xi}ni=1 and algorithm
stated in section 3.4.3.
4. Obtain standard error by {α̂(b), β̂(b)}Bb=1.
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Remark 2 (σn selection). It is convenient to choose a suitable σn before optimizing lα,σn(β).
Let σn = n
− 1
w , where w ∈ R+ can be several candidates. A small w makes R(u;σn) a better
approximation to I(u ≥ 0) as u→ 0, but maybe more unstable in differentiation, thus there is
a trade-off in selecting an appropriate σn. One can use cross-validation to select σn. However,
for convenience one can just subjectively choose one of the candidates mentioned above, since
different σn’s give almost the same results in estimation. Here we use σn = n
− 1
2 in the following
simulation chapter and data analysis chapter.
Remark 3. If β0 is the only parameter to be estimated in cure time, i.e., τ = β0, then we
suggest to obtain the estimate and standard error of τ using grid search directly. Specifically,
let lα(β) be
lα(β) =
∑
δi=0,1
logUD(zi; τ |α) +
∑
i:δi=3
{
logUD(zi; τ |α) + log hT (zi|α)
}
where
hT (zi|α) = hO(zi) + hD(zi|α)I(zi ≤ τ)
UD(zi; τ |α) =
{
SD(zi|α)− SD(τ |α)
}
I(zi ≤ τ) + SD(τ |α).
We suggest to optimize lα(β) using grid search instead of optimizing lα,σn(β). Note that in this
case the estimation does not involve the sigmoid function approximation.
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Chapter 4
Simulation Studies
In this chapter, we conduct simulation to evaluate our proposed method under three simulation
studies. In (S1), four datasets with different distributions are used to validate the methodology
from different aspects. (S2) focuses on demonstrating an application issue in the sense of
mislabelling within δ (O misbabel to D, or vice versa), which makes the simulated dataset
much closer to the real world. (S3) shows the robustness of the cure time estimation against the
misspecification of the model for SD(t). Although one can use different covariates in modelling
SD(t) and τ , respectively, it is natural for a practitioner to use the same covariate X to describe
the behavior of D and the cure time. Therefore, we use the same covariate X to model all
parameters (i.e., X(1) = X(2) = X) in our simulation studies. For each setting, we generate 200
datasets, each with sample size n = 500. The covariate is X = (X0, X1, X2)
T , where X0 is set
to be 1 for the intercept, and (X1, X2)
T is generated from the normal distribution with mean
vector 0 and covariance matrix
Σ =
 1 0.5
0.5 1
 .
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Conditional on X, D is generated from the Weibull distribution with the shape parame-
ter exp(αT1X), where α1 = (α10, α11, α12)
T , and the scale parameter exp(αT2X), where α2 =
(α20, α21, α22)
T . The cure time parameter τ is modelled as τ = exp(βTX), where β = (β0, β1, β2)
T .
The life table of the general population in Taiwan is used to generate O. C is generated from
the Weibull distribution to achieve different censoring rates. For each setting, we calculate
mean and standard deviation (SD) of the estimates, and obtain the standard error (SE) and
the square root mean squared error (SMSE), from 200 bootstrapped samples. For convenience
we subjectively choose σn = n
− 1
2 , since different σn’s give similar results.
4.1 Simulation results under (S1)
In (S1), we evaluate the behaviors of the proposed method under different combinations of
qC = P (Z = C), qO = P (Z = O), qD = P (Z = D), and qT = P (Z = T ). (S1)-1 represents the
ideal situation in which we know exactly if Z = D or Z = O (i.e. qT = 0) for each individual
without censoring. Note that in real world it is a rare case that a dataset contains almost no
censored sample, and it is also rare that we know exactly if Z = D or Z = O for each patient,
due to the difficulty in identifying the underlying cause of death for all patients. Therefore
the information of cause of death in death certificate may contain the garbage codes, which
motivates the usage of δ = 3. (S1)-2 is the same as (S1)-1 except that qC increases. (S1)-3 is
the same as (S1)-1, except that α20 = 3.912, such that qD becomes smaller than (S1)-1. Unlike
those settings with qT = 0, in (S1)-4 we set the qT to be higher. Table 4.1 reports the true
parameter values (True), mean of estimates (Mean), SD, and SE.
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Table 4.1: Simulation results of (S1) under different settings for δ.
(S1)-1
(qC , qO, qD, qT ) = (1%, 41%, 58%, 0%)
Parameter α10 α11 α12 α20 α21 α22 β0 β1 β2
True -0.693 -0.110 0.040 1.946 0.130 0.070 1.792 0.250 -0.300
Mean -0.679 -0.105 0.042 1.926 0.130 0.060 1.755 0.250 -0.305
SD 0.051 0.065 0.065 0.127 0.146 0.141 0.024 0.040 0.036
SE 0.063 0.074 0.074 0.145 0.166 0.168 0.021 0.039 0.040
(S1)-2
(qC , qO, qD, qT ) = (34%, 11%, 55%, 0%)
Parameter α10 α11 α12 α20 α21 α22 β0 β1 β2
True -0.693 -0.110 0.040 1.946 0.130 0.070 1.792 0.250 -0.300
Mean -0.677 -0.112 0.040 1.935 0.155 0.065 1.743 0.346 -0.299
SD 0.054 0.068 0.070 0.136 0.159 0.151 0.029 0.060 0.055
SE 0.065 0.075 0.076 0.154 0.174 0.175 0.032 0.057 0.057
(S1)-3
(qC , qO, qD, qT ) = (3%, 69%, 28%, 0%)
Parameter α10 α11 α12 α20 α21 α22 β0 β1 β2
True -0.693 -0.110 0.040 3.912 0.130 0.070 1.792 0.250 -0.300
Mean -0.668 -0.105 0.032 3.861 0.116 0.108 1.741 0.243 -0.292
SD 0.082 0.090 0.097 0.255 0.292 0.303 0.033 0.071 0.065
SE 0.098 0.110 0.110 0.309 0.333 0.336 0.033 0.060 0.060
(S1)-4
(qC , qO, qD, qT ) = (2%, 12%, 17%, 69%)
Parameter α10 α11 α12 α20 α21 α22 β0 β1 β2
True -0.693 -0.110 0.040 1.946 0.130 0.070 1.792 0.250 -0.300
Mean -0.660 -0.106 0.037 1.904 0.108 0.068 1.762 0.251 -0.298
SD 0.054 0.073 0.067 0.126 0.147 0.144 0.030 0.036 0.038
SE 0.065 0.076 0.076 0.146 0.165 0.166 0.029 0.039 0.040
Since (S1)-1 is the ideal situation, we can obtain correct estimates, and the bootstrapped
SE is similar to the SD for all parameters. The main difference between (S1)-1 and (S1)-2 is
qC and qO, In (S1)-1, qC = 1% and qO = 41%; in (S1)-2, qC = 34% and qO = 11%. The SD
and the SE in (S1)-2 are all slightly larger than that of the corresponding estimates in (S1)-1.
It makes sense that the higher SD exists in a data containing more censored cases.
The main difference between (S1)-1 and (S1)-3 is qO and qD, In (S1)-1, qO = 41% and
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qD = 58%; in (S1)-3, qO = 69% and qD = 28%. The smaller qD in (S1)-3 means fewer
information of constraints contribute to the estimation process, thus less efficient estimates are
obtained. Therefore, the SD and the SE in (S1)-3 are all larger than that of the corresponding
estimates in (S1)-1.
(S1)-4 aims to mimic the situation that most of the exact statuses for (O,D) are not
available, where one can only observe Z = T for most of the uncensored subjects. The SD
and the SE in (S1)-4 are slightly larger than that of the corresponding estimates in (S1)-1.
Note that the information used in estimation is quite different between (S1)-1 and (S1)-4. The
estimation even works in a (O,D) unclear dataset, with similar SD between (S1)-1 and (S1)-4.
Also note that the similar estimation between (S1)-1 and (S1)-4 may be resulted from that
(S1)-1 naturally contains higher percentage of D. The comparison with lower percentage of D
will be further demonstrated in study-(S2).
4.2 Simulation results under (S2)
In this simulation, we show a situation in which the status of O is partly mislabelling to D and
vice versa, which implies a poor cause of death quality. To avoid using wrong information of
(O,D), we arbitrarily set a portion of (O,D) to be T . We also arbitrarily set all (O,D) to be
T to see the robustness of our method.
(S2)-1 represents the ideal case where the exact status for (O,D) are available. (S2)-2
mimics the situation where some status of (O,D) are wrongly identified, where the proportions
that δ = 2 is mislabelled as δ = 1 and δ = 1 is mislabelled as δ = 2 are in total 5%. (S2)-3
uses the same data with (S2)-2, except that 50% of subjects with δ = 2 are treated as δ = 3
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to enter the analysis. (S2)-4 adopts the same strategy with (S2)-3 but all uncensored subjects
are coded as δ = 3. Since coding δ = 3 will not be affected by the mislabelling between (O,D),
we would expect a better analysis result of (S2)-3 and (S2)-4 than (S2)-2 in the presence of
mislabelling. Figure 4.1 summarizes the relationships between different settings. Simulation
results are reported in Table 4.2.
Ideal data
(S2)-1
Mislabeled
data (S2)-2
(S2)-3 (S2)-4
(O,D) mislabel 5%
Treated partial D to be T Treated all O and D to be T
Figure 4.1: (O,D) mislabelling simulation design
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Table 4.2: Mislabelling (O,D) simulation result.
(S2)-1
(qC , qO, qD, qT ) = (2%, 57%, 41%, 0%), mislabelling rate = 0%
Parameter α10 α11 α12 α20 α21 α22 β0 β1 β2
True -0.693 -0.110 0.040 3.401 0.300 -0.400 2.303 0.250 -0.300
Mean -0.663 -0.112 0.046 3.338 0.293 -0.408 2.256 0.245 -0.293
SD 0.066 0.078 0.079 0.172 0.199 0.202 0.031 0.051 0.048
SMSE 0.073 0.078 0.079 0.183 0.199 0.202 0.056 0.051 0.049
(S2)-2
(qC , qO, qD, qT ) = (2%, 57%, 41%, 0%), mislabelling rate = 5%
Parameter α10 α11 α12 α20 α21 α22 β0 β1 β2
True -0.693 -0.110 0.040 3.401 0.300 -0.400 2.303 0.250 -0.300
Mean -0.967 -0.020 -0.037 4.589 0.000 -0.120 4.099 0.042 -0.013
SD 0.058 0.073 0.081 0.253 0.351 0.368 0.250 0.539 0.515
SMSE 0.280 0.116 0.111 1.214 0.461 0.462 1.814 0.576 0.589
(S2)-3
(qC , qO, qD, qT ) = (2%, 57%, 20.5%, 20.5%), mislabelling rate = 5%
Parameter α10 α11 α12 α20 α21 α22 β0 β1 β2
True -0.693 -0.110 0.040 3.401 0.300 -0.400 2.303 0.250 -0.300
Mean -0.755 -0.093 0.023 3.854 0.258 -0.353 2.412 0.131 -0.121
SD 0.134 0.089 0.093 0.537 0.316 0.320 0.735 0.283 0.311
SMSE 0.147 0.090 0.094 0.701 0.318 0.323 0.742 0.307 0.359
(S2)-4
(qC , qO, qD, qT ) = (2%, 0%, 0%, 98%), mislabelling rate = 5%
Parameter α10 α11 α12 α20 α21 α22 β0 β1 β2
True -0.693 -0.110 0.040 3.401 0.300 -0.400 2.303 0.250 -0.300
Mean -0.586 -0.093 0.013 3.168 0.202 -0.284 2.505 0.212 -0.320
SD 0.078 0.089 0.087 0.165 0.210 0.201 0.636 0.230 0.261
SMSE 0.133 0.091 0.091 0.286 0.231 0.232 0.666 0.232 0.261
Obviously, (S2)-2 shows worse estimation result than (S2)-1 because of the mislabelling.
Moreover, mislabelling affects a lot even when the mislabelling rate is small. In the estimation
of (S2)-2, the mislabelling rate 5% causes much more bias and much higher SD of all estimates
than (S2)-1. Both (S2)-3 and (S2)-4 give more accurate estimates than that of (S2)-2 even if
there exists mislabelling information. (S2)-4 performs better than (S2)-3 from the perspective
of SMSE, since (S2)-3 can still affected by mislabelling, while (S2)-4 does not. It implies that
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in real applications, one is suggested to set the status of an unclear cause of death to be δ = 3
(Z = T ) to avoid poor estimation.
4.3 Simulation results under (S3)
In this simulation study, we show the robustness of the cure time estimation when SD(t) was
misspecified. In order to see how bias affect the cure time estimate, we estimate τ by using
both the correct distribution (Weibull distribution), and incorrect distribution (log-normal
distribution) to model the distribution of D. Note that in this simulation, the shape parameter
of Weibull distribution corresponds to increasing hazards. However, the log-normal distribution
has the limitation to model an increasing hazard, therefore it is obvious that the misspecifying
distribution of D would lead to a poor estimation.
D is generated from Weibull distribution such that qO > qD, which means that this simulated
patient population is more likely to death from O (general cause) than D (disease). That is,
we simulate mild disease patient population. In (S3)-1 we use the almost uncensored data; in
(S3)-2 we use the same data as (S3)-1, but (O,D) is converted to T (denoted by (O,D)→ T );
in (S3)-3 we use the censored data; in (S3)-4 weuse the same data as (S3)-3, but (O,D) is all
converted to T . Simulation results are reported in Table 4.3.
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Table 4.3: Influence of distribution misspecification
on mild disease patient population.
SD(t) Weibull (correct) Log-normal (incorrect)
τ = exp(βTX) β0 β1 β2 β0 β1 β2
(S3)-1
(qC , qO, qD, qT ) = (1%, 41%, 58%, 0%)
True 2.303 0.250 -0.300 2.303 0.250 -0.300
Mean 2.289 0.249 -0.298 2.290 0.253 -0.302
SD 0.008 0.015 0.016 0.009 0.017 0.016
SMSE 0.016 0.015 0.016 0.015 0.017 0.017
(S3)-2
(qC , qO, qD, qT ) = (1%, 0%, 0%, 99%)
True 2.303 0.250 -0.300 2.303 0.250 -0.300
Mean 2.296 0.249 -0.299 2.304 0.255 -0.306
SD 0.015 0.021 0.022 0.023 0.028 0.026
SMSE 0.016 0.021 0.022 0.023 0.028 0.027
(S3)-3
(qC , qO, qD, qT ) = (41%, 16%, 43%, 0%)
True 2.303 0.250 -0.300 2.303 0.250 -0.300
Mean 2.271 0.249 -0.298 2.274 0.254 -0.304
SD 0.027 0.043 0.044 0.030 0.043 0.047
SMSE 0.042 0.043 0.044 0.041 0.043 0.047
(S3)-4
(qC , qO, qD, qT ) = (41%, 0%, 0%, 59%)
True 2.303 0.250 -0.300 2.303 0.250 -0.300
Mean 2.287 0.250 -0.301 2.307 0.248 -0.305
SD 0.048 0.051 0.057 0.067 0.063 0.064
SMSE 0.050 0.051 0.057 0.067 0.063 0.064
In Table 4.3, we can see that the correct (Weibull) and incorrect (log-normal) distribution
specification have similar cure time SMSE in all settings. The estimation of completed data
((S3)-1 and (S3)-2) have smaller SMSE than that of censored data ((S3)-3 and (S3)-4), respec-
tively. The estimation of data without (O,D) → T ((S3)-1 and (S3)-3) have smaller SMSE
than that with (O,D)→ T ((S3)-2 and (S3)-4), respectively. (S3) shows the robustness on the
estimation of cure time when distribution is misspecified. This property ensures the correctness
of cure time estimation even if a wrong parametric distribution is specified for SD(t).
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Chapter 5
Data Analysis
5.1 Cure time estimation of 22 major cancers in Taiwan
We analyze the cancer data from the National Cancer Registry Database of the Taiwan Cancer
Registry, in which all patients were diagnosed between 2004 and 2015, and follow-up to 2016.
Taiwan Cancer Registry database is good for population-based cancer survival analysis because
of both high qualities of cancer registry database and death certificate database.
In order to conduct a reliable estimation of the cure time, we suggest the following steps,
where we use colorectal cancer as an example to illustrate the analysis procedure.
1. Draw ST (t|c) and SO(t|c),∀ t > c in some subjectively chosen time points such as c ∈
{1, 3, 5, . . .} to check if statistical cure exists. According to Figure 5.1, we can see that
Figure 5.1(e) satisfies statistical cure (2.1), that is, ST (t|10) = SO(t|10) ∀ t > 10. It is
suggested that the cure time exists and is between 7 years and 10 years. Therefore we
can use CTM to estimate the cure time.
2. Estimate cure time τ through the cure time model. We use Weibull model, log-normal
35
(a) k = 1 (b) k = 3 (c) k = 5
(d) k = 7 (e) k = 10 (f) k = τ̂
Figure 5.1: ST (t|k) and SO(t|k) of colorectal cancer data and general population in Taiwan, for
k = 1, 3, 5, 7, 10, and τ̂ years.
model, and log-logistic model, to model D. After obtaining the estimated cure time of
the corresponding three parametric distributions, we choose the estimated cure time with
the largest log-likelihood value among the three parametric models. The estimated cure
time of, for example, colorectal cancer, is τ̂ = 7.85 years from fitting a log-normal model.
3. Draw ST (t|τ̂) and SO(t|τ̂) to check if τ̂ satisfies the definition of statistical cure: ST (t|τ) =
SO(t|τ),∀ t > τ . From Figure 5.1(f) we can see that 7.85 years seems to be a reason-
able estimate, since it satisfies the definition of statistical cure, that is, ST (t|7.85) =
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SO(t|7.85) ∀ t > 7.85.
The above steps are summarized in Figure 5.2.
Draw ST (t|c) and SO(t|c),∀ t > c, in some subjectively chosen time
points such as c ∈ {1, 3, 5, . . .} to check if statistical cure exists
Stop
Estimate cure time τ through
the cure time model
Draw ST (t|τ̂) and SO(t|τ̂),∀ t > τ̂ , to
check if τ̂ satisfies the definition of statis-
tical cure: ST (t|τ) = SO(t|τ),∀ t > τ
No statistical cure Statistical cure may exist
Figure 5.2: Cure time estimation flow chart
In Global Burden of Disease (GBD, 2016), the cure time is roughly defined as 10 years
for all diseases. In The Burden of Cancer New Zealand 2006 (Blakely et al., 2010), the cure
time is defined based on visually identification through the relative survival curves. Using our
proposed method, we calculated cure time on 22 cancer sites and compare with the result from
New Zealand. We also calculate cure time using a convenient method from Janssen-Heijnen
et al. (2007, 2010); Dal Maso et al. (2014), which is the smallest time point such that the
conditional relative survival exceeds 95% (denoted by CRS95) or 99% (denoted by CRS99).
The results are shown in Table 5.1.
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From Table 5.1, the cancer sites gallbladder, kidney and other urinary, larynx, leukaemia,
oesophagus, ovary, and testis have the estimated cure time similar to both the CRS method
CRS95 and CRS99. The rest 15 cancer sites, however, have large differences comparing to the
results of CRS95 and CRS99. Among these sites, the objectively estimated cure time from
data may be more reasonable than either the CRS method, or visually identification using
relative survival curve. Although Janssen-Heijnen et al. (2007, 2010) suggested to use 95%
and 99% as the threshold, the CRS method is not reliable since the threshold is determined
subjectively. Figure 5.3 shows the conditional survival from cervical cancer with estimated
cure time from different methods. We can see that the estimated cure time from CRS95 (4.84
years) (Figure 5.3(b)) and from Blakely et al. (2010) (5 years) (Figure 5.3(d)) obviously do not
attain statistical cure. The estimated cure time from CTM (8.58 years) (Figure 5.3(a)) and
from CRS99 (10.28 years) (Figure 5.3(c)) both attain the statistical cure, but CTM gives a
more reasonable and smaller estimate than CRS99, which is, by Definition 1, the smallest time
point satisfying (2.1). We show the same graphical judgement from Figure E.1 to Figure E.21
for the rest cancer sites.
We further observe that the differences between the CTM estimated cure time and the last
observed time are all less than 1 year among kidney and other urinary, liver, oesophagus, and
ovary, which implies that we may not obtain stable cure time estimate until those corresponding
follow-up time are long enough. One can still calculate these cure time, but we do not recom-
mend using these results in application, since all we know about the statistical cure information
of these cancer sites is that the cure time are larger than the last observed time.
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(a) τ̂ = 8.58 from CTM (b) τ̂ = 4.84 from CRS95
(c) τ̂ = 10.28 from CRS99 (d) τ̂ = 5 from New Zealand
(e) CTM-based net survival (f) Relative survival
Figure 5.3: ST (t|k) and SO(t|k) of cervical cancer data and general population in Taiwan, where
k is cure time estimated from CTM, CRS95, CRS99, and New Zealand (2006). (5.3a-5.3d).
Model-based net survival and relative survival (5.3e, 5.3f), horizontal and vertical dashed lines
represent locations of CTM-estimated cure time and cure rate, respectively.
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Table 5.1: Statistical cure time of 22 cancer sites in Taiwan, diagnosed between 2004 and
2015, follow-up to 2016.
Cancer type Case Number
Follow-up
(years)
Cure time (years)
Cure rate (se)Taiwan New Zealand
(years)
CTM (se) CRS95a CRS99b
Bladder 14,210 9.65 6.56 (0.029) 6.68 8.88 10 0.56 (0.005)
Bone and connective 471 11.78 5.36 (0.881) 7.65 7.65 10 0.66 (0.047)
Breast (female)1 100,845 13.00 12.15*(0.020) 7.67 11.58 20 0.75 (0.002)
Cervix 18,625 13.00 8.58 (0.018) 4.84 10.28 5 0.65 (0.005)
Colorectum2 126,309 13.00 7.85 (0.099) 5.07 7.97 8 0.54 (0.003)
Gallbladder 1,101 6.83 5.74 (0.479) 5.74 5.74 7 0.16 (0.023)
Hodgkin 1,298 12.12 7.16 (1.250) 3.02 7.05 10 0.79 (0.024)
Kidney and other urinary 3,352 6.96 7.00*(0.535) 6.48 6.48 10 0.52 (0.025)
Larynx 2,549 7.98 4.27 (0.521) 3.64 4.06 10 0.63 (0.023)
Leukaemia 13,109 12.50 8.01 (1.064) 8.01 8.01 10 0.37 (0.018)
Lip mouth pharynx6 80,256 13.00 7.66 (0.005) 9.50 12.18 10 0.45 (0.002)
Liver5 116,843 13.00 12.01*(0.061) 10.68 12.27 7 0.18 (0.001)
Lung trachea bronchus3 112,862 13.00 6.90 (0.003) 9.08 11.38 6 0.14 (0.001)
Non-Hodgkin lymphoma 14,052 12.96 6.00 (0.592) 12.86 12.86 20 0.58 (0.012)
Oesophagus 17,379 9.00 7.33 (0.060) 8.02 8.45 6 0.09 (0.002)
Ovary 8,263 7.99 7.51*(0.249) 6.34 7.50 10 0.57 (0.011)
Pancreas 2,674 7.71 3.52 (0.315) 6.39 6.39 5 0.11 (0.010)
Prostate4 32,779 9.00 7.31 (0.022) 2.87 5.38 20 0.72 (0.004)
Stomach9 26,954 9.46 5.36 (0.007) 5.79 8.33 6 0.33 (0.003)
Testis 294 7.32 4.02 (0.537) 4.02 4.02 3 0.88 (0.034)
Thyroid8 4,032 7.52 6.31 (0.671) 1.46 6.31 5 0.94 (0.006)
Uterus7 13,005 12.15 5.76 (0.116) 2.77 5.37 6 0.80 (0.005)
a,b The smallest time point such that the conditional relative survival exceeds 95% (CRS95) or 99% (CRS99) (Janssen-Heijnen
et al., 2007, 2010; Dal Maso et al., 2014)
1-9 1st to 9th major cancers in Taiwan Cancer Registry Annual Report 2016.
* No statistical cure. The estimated cure times, which are mostly close to the last observed time, are still shown in the table.
5.2 Taiwan colorectal cancer data analysis
In population-based studies, although it is enough for one to apply the method described in
Section 5.1 to obtain cure time estimate, some drawbacks should be noted. First, one may
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obtain not reliable cure time estimate if the strata has few amount of patients. Second, the
statistical inference related to the cure time comparison may be hard to conduct. In this section,
we aim to reveal usage of CTM by incorporating covariates. In order to make sure that the
CTM can be used with covariates, we suggest the following steps, and using colorectal cancer
as an example:
1. For each strata x of covariate X, draw ST (t|c;X = x) and SO(t|c;X = x),∀ t > c in
some subjectively chosen time points such as c ∈ {1, 3, 5, . . .} to check if statistical cure
exists. In this example, X = (Age, Sex, Stage) and the strata is (Age, Sex, Stage) =
(60-69, Male, II). According to Figure 5.4, we can see that Figure 5.4(e) and Figure
5.4(f) satisfies statistical cure (2.1) visually.
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(a) k = 0 (b) k = 1 (c) k = 3
(d) k = 5 (e) k = 7 (f) k = 10
Figure 5.4: ST (t|k) and SO(t|k) of 60-69 years old, male, stage II colorectal cancer data and
corresponding general population in Taiwan, for k = 0, 1, 3, 5, 7, and 10 years.
2. Suppose there are m strata with statistical cure, we then incorporate these m strata to
build up the cure time model.
The steps above are summarized in Figure 5.5.
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For each strata x of covariate X, draw ST (t|c;X = x) and
SO(t|c;X = x),∀ t > c in some subjectively chosen time points
such as c ∈ {1, 3, 5, . . .} to check if statistical cure exists
Incorporate all m strata with statistical cure to build up the CTM
There are m strata with statistical cure
Figure 5.5: CTM estimation flow chart
We use the process stated on Figure 5.5. There is no statistical cure being observed on all
strata containing age group 80+ and stage IV, therefore we exclude all strata containing age
group 80+ and stage IV. One can imagine that there is no statistical cure in older or late stage
patient population.
Table 5.2: Cure time model on colorectal cancer of Taiwan Cancer Reg-
istry.
(qC , qO, qD, qT ) = (73%, 4%, 16%, 7%)
Intercept
Sex Age Stage
Male 50-59 60-69 70-79 II III
µ = αT1 X α10 α11 α12 α13 α14 α15 α16
Estimate 3.9190 -0.3123 0.1252 -0.1120 -0.9219 -0.3702 -1.1455
SE 0.0405 0.0286 0.0470 0.0433 0.0379 0.0396 0.0360
p-value < 0.0001 < 0.0001 0.0040 < 0.0001 < 0.0001 < 0.0001 < 0.0001
σ = αT2 X α20 α21 α22 α23 α24 α25 α26
Estimate 1.6166 -0.0090 0.1443 0.2115 0.2304 0.0800 -0.1152
SE 0.0312 0.0232 0.0348 0.0344 0.0310 0.0310 0.0280
p-value < 0.0001 0.2560 < 0.0001 < 0.0001 < 0.0001 < 0.0001 0.0120
τ = exp(βTX) β0 β1 β2 β3 β4 β5 β6
Estimate 2.2404 -0.0012 0.0060 0.0021 0.0024 -0.0278 -0.0371
SE 0.0054 0.0027 0.0046 0.0040 0.0040 0.0051 0.0048
p-value < 0.0001 0.7040 0.1560 0.4720 0.3880 < 0.0001 < 0.0001
43
After excluding those patients with age group 80+ or stage IV, 75,944 colorectal cancer
patients in Taiwan are included in the analysis. The covariate
X = {Sex (female is reference), Age group (50- is reference), Stage (stage I is reference)}
is used to build up the CTM. Log-normal distribution is used to model D with parameter
µ = αT1X and σ = α
T
2X, where α1 = {α10, α11, . . . , α16}, and α2 = {α20, α21, . . . , α26}. The
standard error (SE) and two-sided p-value are obtained from 500 bootstrapping.
Table 5.2 shows the estimation result. Note that both sex and age group show non-significant
effect relative to cure time, and the cure time of both stage II and stage III are significant lower
than the cure time of stage I. With fixed sex and age group, a stage I colorectal cancer patient
has the estimated cure time exp(2.2404) = 9.3971 years, the estimated cure time is exp(2.2404−
0.0278) = 9.1394 years for stage II patient, and the estimated cure time is exp(2.2404−0.0371) =
9.0548 years for stage III patient. Those statistical cure stage III patients may be distinguishable
from uncure patients earlier than that of stage II patients, and those statistical cure stage II
patients may be distinguishable from uncure patients earlier than that of stage I patients. This
example provides a typical application guide in both National Burden of Disease studies and
population-based studies.
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Chapter 6
Discussion
For decades, cure rate can be obtained by the appropriate cure rate model to help public health
policy making. Cure time, however, was obtained by visually identifying the time point of non-
declination in the non-parametric net survival curve. This study enables us to obtain cure
time estimate with solid statistical properties. In this study, we propose a new definition of
statistical cure in (2.1), and develop a parametric method CTM to estimate the cure time.
The cure time model has several good properties, and we investigate these properties through
simulations. (S1) shows that the CTM estimation works in highly censored data; (S2) shows
the robustness of CTM by estimating the cure time from mislabelled data sets; (S3) shows the
robustness of CTM against the misspecification of SD(.)
In application, practitioners can obtain the estimate of cure time through the proposed
CTM. Covariates can also be involved in the cure time model with a well-prepared data in
which each strata has a cure time.
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To estimate cure time, we propose a random variable representation in Theorem 2, that is
T = min(O,D) · I(D ≤ τ) +O · I(D > τ)
with cure time τ embedded in T . Note that the conventional mixture cure rate model has a
similar form
T = min(O,D) · I(R = 1) +O · I(R = 0),
and so does non-mixture cure rate model
T = min(O,D) · I(N > 0) +O · I(N = 0),
where R ∼ Bernoulli(pi) and N ∼ Poisson(λ), and pi = P (N = 0) = e−λ. The advantage of
the proposed random variable representation (2.3) is that one can obtain both cure time τ and
cure rate P (D > τ), while the conventional cure rate model can only obtain the cure rate.
The cause of death information usage issue is important. In the previous population-based
methodologies it was suggested using T and ignore death certificate information (O,D) com-
pletely (Howlader et al., 2010; Huang et al., 2014). In this study we derive the likelihood
(Theorem 3) that allows the usage of partial or full death certificate information, to help ob-
tain more efficient estimate. In Taiwan, we have high quality of death certificate system, the
ignorance of this information does not make sense. The conventional approaches that ignore
all death certificate information are just a special case in our perspective of likelihood function
derivation. Using this concept, researchers may improve the conventional cure rate model with
(O,D) involving in likelihood function.
Although the proposed methodology enable us to obtain the cure time point estimate, we
should keep in mind that there are assumptions and limitations. Since the cure time model
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can be used if the cure time is assumed to be in the model, we have to use graphical check
as a diagnostics tool stated in Chapter 5. Although we show consistency and robustness in
the simulation setting, so far we do not derive the asymptotics and robustness properties of
cure time estimate. Moreover, it is time consuming in obtaining bootstrapped standard error,
the computational cost is non-negligible, especially in large population size data analysis. The
above limitations are all important to be dealt with in future direction.
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Appendix A
Proof of Lemma 1
Proof. Derive S(t) directly, we have
S(t) = P (T > t|R = 1)P (R = 1) + P (T > t|R = 0)P (R = 0)
= P (min(O,D) > t|R = 1)pi + P (min(O,D) > t|R = 0)(1− pi)
= P (O > t|R = 1)pi + P (min(O,D) > t)(1− pi)
= P (O > t|R = 1)pi + P (O > t|R = 0)P (D > t|R = 0)(1− pi)
= P (O > t)pi + P (O > t)P (D > t|R = 0)(1− pi)
= P (O > t) [pi + (1− pi)P (D > t|R = 0)]
= SO(t) [pi + (1− pi)Su(t)] .
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Appendix B
Proof of Lemma 2
Proof. Deriving directly, we have
S(t) = P (T > t|N = 0)P (N = 0) +
∞∑
n=1
P (T > t|N = n)P (N = n)
= P (min(O,D) > t|N = 0)P (N = 0) +
∞∑
n=1
P (min(O,D) > t|N = n)P (N = n)
= P (O > t|N = 0)P (N = 0) +
∞∑
n=1
P (O > t|N = n)P (D > t|N = n)P (N = n)
= P (O > t)P (N = 0) +
∞∑
n=1
P (O > t)P (D > t|N = n)P (N = n)
= P (O > t)
[
P (N = 0) +
∞∑
n=1
P (min (D1, . . . , Dn) > t)P (N = n)
]
= P (O > t)
[
P (N = 0) +
∞∑
n=1
[1− F0(t)]nP (N = n)
]
= P (O > t)
∞∑
n=0
[1− F0(t)]nλ
ne−λ
n!
= P (O > t)
e−λ
e−[λ(1−F0(t))]
∞∑
n=0
[(1− F0(t))λ]ne−[(1−F0(t))λ]
n!
= P (O > t)
e−λ
e−[λ(1−F0(t))]
= P (O > t)e−λF0(t) = SO(t)piF0(t).
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Appendix C
Proof of Theorem 1
Proof. By (1.1), the left hand side of (2.1) can be expressed as
S(t|τ) = SO(t)SD(t)
SO(τ)SD(τ)
∀ t ≥ τ.
And the right hand side of (2.1) is
SO(t|τ) = SO(t)
SO(τ)
∀ t ≥ τ.
After some simplification, we have
SD(t) = SD(τ) ∀ t ≥ τ.
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Appendix D
Proof of Theorem 2
Proof. We first show that (2.1) implies Theorem 2(b). Since S(t|τ) = exp {− [H(t)−H(τ)]},
(2.1) can also be expressed as
H(t)−H(τ) = HO(t)−HO(τ). (D.1)
Considering the assumption of independence between O and D (1.1), the left hand side of (D.1)
can be expressed as
HO(t) +HD(t)−HO(τ)−HD(τ) = HO(t)−HO(τ),
which implies that
HD(t)−HD(τ) =
∫ t
τ
hD(u)du = 0.
Since hD(t) ≥ 0 ∀ t, we must have hD(t) = 0 ∀ t > τ . Thus Theorem 2(b) follows.
We next show that Theorem 2(b) implies (2.1). Integrate both sides of Theorem 2(b) gives
H(t) = HO(t) +HD(τ) ∀ t > τ,
54
and we have
S(t) = SO(t)SD(τ) ∀ t > τ. (D.2)
Divide left sides of (D.2) by S(τ), and right side of (D.2) by SO(τ)SD(τ), we get (2.1).
Then we show that Theorem 2(a) implies (2.1). Under (1.1), the survival function of T is
S(t) = P (T > t) = P (min(O,D) · I(D ≤ τ) +O · I(D > τ) > t)
= P (min(O,D) > t,D ≤ τ) + P (O > t,D > τ)
= P (O > t) [P (t < D ≤ τ) + P (D > τ)]
= SO(t) {[SD(t)− SD(τ)] · I(t ≤ τ) + SD(τ)} .
Then we have
S(t|τ) = S(t)
S(τ)
=
SO(t) {[SD(t)− SD(τ)] · I(t ≤ τ) + SD(τ)}
SO(t)SD(τ)
= SO(t|τ) ∀t > τ.
(2.1) follows.
Finally we show that Theorem 2(b) implies Theorem 2(a). Under (1.1), Theorem 2(b) can
be expressed as
S(t) = SO(t) [SD(t)I(t ≤ τ) + SD(τ)I(t > τ)]
= SO(t) {[SD(t)− SD(τ)] · I(t ≤ τ) + SD(τ)}
= P (O > t)P (t < D < τ) + P (O > t)P (D > τ)
= P (O > t, t < D < τ) + P (O > t,D > τ)
= P (min(O,D) · I(D ≤ τ) +O · I(D > τ) > t).
Thus Theorem 2(a) follows.
55
Appendix E
Figures of ST (t|k) and SO(t|k) of 21
major cancers in Taiwan
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(a) τ̂ = 6.56 from CTM (b) τ̂ = 6.68 from CRS95
(c) τ̂ = 8.88 from CRS99 (d) τ̂ = 10 from New Zealand
(e) CTM-based net survival (f) Relative survival
Figure E.1: ST (t|k) and SO(t|k) of bladder cancer data and general population in Taiwan,
where k is cure time estimated from CTM, CRS95, CRS99, and New Zealand (2006) (E.1a-
E.1d). Model-based net survival and relative survival (E.1e, E.1f), horizontal and vertical
dashed lines represent locations of CTM-estimated cure time and cure rate, respectively. Note
that in E.1d there is no ST (t|k) and SO(t|k) since the follow-up time (9.65 years) is smaller
than the cure time (10 years).
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(a) τ̂ = 5.36 from CTM (b) τ̂ = 7.65 from CRS95
(c) τ̂ = 7.65 from CRS99 (d) τ̂ = 10 from New Zealand
(e) CTM-based net survival (f) Relative survival
Figure E.2: ST (t|k) and SO(t|k) of Bone and connective cancer data and general population in
Taiwan, where k is cure time estimated from CTM, CRS95, CRS99, and New Zealand (2006)
(E.2a-E.2d). Model-based net survival and relative survival (E.2e, E.2f), horizontal and vertical
dashed lines represent locations of CTM-estimated cure time and cure rate, respectively.
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(a) τ̂ = 12.15 from CTM (b) τ̂ = 7.67 from CRS95
(c) τ̂ = 11.58 from CRS99 (d) τ̂ = 20 from New Zealand
(e) CTM-based net survival (f) Relative survival
Figure E.3: ST (t|k) and SO(t|k) of female breast cancer data and general population in Taiwan,
where k is cure time estimated from CTM, CRS95, CRS99, and New Zealand (2006) (E.3a-
E.3d). Model-based net survival and relative survival (E.3e, E.3f), horizontal and vertical
dashed lines represent locations of CTM-estimated cure time and cure rate, respectively. Note
that in E.3d there is no ST (t|k) and SO(t|k) since the follow-up time (13 years) is smaller than
the cure time (20 years).
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(a) τ̂ = 7.85 from CTM (b) τ̂ = 5.07 from CRS95
(c) τ̂ = 7.97 from CRS99 (d) τ̂ = 8 from New Zealand
(e) CTM-based net survival (f) Relative survival
Figure E.4: ST (t|k) and SO(t|k) of colorectal cancer data and general population in Taiwan,
where k is cure time estimated from CTM, CRS95, CRS99, and New Zealand (2006) (E.4a-
E.4d). Model-based net survival and relative survival (E.4e, E.4f), horizontal and vertical
dashed lines represent locations of CTM-estimated cure time and cure rate, respectively.
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(a) τ̂ = 5.74 from CTM (b) τ̂ = 5.74 from CRS95
(c) τ̂ = 5.74 from CRS99 (d) τ̂ = 7 from New Zealand
(e) CTM-based net survival (f) Relative survival
Figure E.5: ST (t|k) and SO(t|k) of gallbladder cancer data and general population in Taiwan,
where k is cure time estimated from CTM, CRS95, CRS99, and New Zealand (2006). (E.5a-
E.5d). Model-based net survival and relative survival (E.5e, E.5f), horizontal and vertical
dashed lines represent locations of CTM-estimated cure time and cure rate, respectively. Note
that in E.5d there is no ST (t|k) and SO(t|k) since the follow-up time (6.83 years) is smaller
than the cure time (7 years).
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(a) τ̂ = 7.16 from CTM (b) τ̂ = 3.02 from CRS95
(c) τ̂7.05 from CRS99 (d) τ̂ = 10 from New Zealand
(e) CTM-based net survival (f) Relative survival
Figure E.6: ST (t|k) and SO(t|k) of Hodgkin lymphoma data and general population in Taiwan,
where k is cure time estimated from CTM, CRS95, CRS99, and New Zealand (2006). (E.6a-
E.6d). Model-based net survival and relative survival (E.6e, E.6f), horizontal and vertical
dashed lines represent locations of CTM-estimated cure time and cure rate, respectively.
62
(a) τ̂ = 7 from CTM (b) τ̂ = 6.48 from CRS95
(c) τ̂ = 6.48 from CRS99 (d) τ̂ = 10 from New Zealand
(e) CTM-based net survival (f) Relative survival
Figure E.7: ST (t|k) and SO(t|k) of kidney and other urinary cancer data and general population
in Taiwan, where k is cure time estimated from CTM, CRS95, CRS99, and New Zealand (2006).
(E.7a-E.7d). Model-based net survival and relative survival (E.7e, E.7f), horizontal and vertical
dashed lines represent locations of CTM-estimated cure time and cure rate, respectively. Note
that in E.7d there is no ST (t|k) and SO(t|k) since the follow-up time (6.96 years) is smaller
than the cure time (10 years).
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(a) τ̂ = 4.27 from CTM (b) τ̂ = 3.64 from CRS95
(c) τ̂ = 4.06 from CRS99 (d) τ̂ = 10 from New Zealand
(e) CTM-based net survival (f) Relative survival
Figure E.8: ST (t|k) and SO(t|k) of larynx cancer data and general population in Taiwan, where
k is cure time estimated from CTM, CRS95, CRS99, and New Zealand (2006). (E.8a-E.8d).
Model-based net survival and relative survival (E.8e, E.8f), horizontal and vertical dashed lines
represent locations of CTM-estimated cure time and cure rate, respectively. Note that in E.8d
there is no ST (t|k) and SO(t|k) since the follow-up time (7.98 years) is smaller than the cure
time (10 years).
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(a) τ̂ = 8.01 from CTM (b) τ̂ = 8.01 from CRS95
(c) τ̂ = 8.01 from CRS99 (d) τ̂ = 10 from New Zealand
(e) CTM-based net survival (f) Relative survival
Figure E.9: ST (t|k) and SO(t|k) of leukaemia data and general population in Taiwan, where
k is cure time estimated from CTM, CRS95, CRS99, and New Zealand (2006). (E.9a-E.9d).
Model-based net survival and relative survival (E.9e, E.9f), horizontal and vertical dashed lines
represent locations of CTM-estimated cure time and cure rate, respectively.
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(a) τ̂ = 7.66 from CTM (b) τ̂ = 9.50 from CRS95
(c) τ̂ = 12.18 from CRS99 (d) τ̂ = 10 from New Zealand
(e) CTM-based net survival (f) Relative survival
Figure E.10: ST (t|k) and SO(t|k) of lip, mouth, and pharynx cancer data and general population
in Taiwan, where k is cure time estimated from CTM, CRS95, CRS99, and New Zealand (2006).
(E.10a-E.10d). Model-based net survival and relative survival (E.10e, E.10f), horizontal and
vertical dashed lines represent locations of CTM-estimated cure time and cure rate, respectively.
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(a) τ̂ = 12.01 from CTM (b) τ̂ = 10.68 from CRS95
(c) τ̂ = 12.27 from CRS99 (d) τ̂ = 7 from New Zealand
(e) CTM-based net survival (f) Relative survival
Figure E.11: ST (t|k) and SO(t|k) of liver cancer data and general population in Taiwan, where
k is cure time estimated from CTM, CRS95, CRS99, and New Zealand (2006). (E.11a-E.11d).
Model-based net survival and relative survival (E.11e, E.11f), horizontal and vertical dashed
lines represent locations of CTM-estimated cure time and cure rate, respectively.
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(a) τ̂ = 6.90 from CTM (b) τ̂ = 9.08 from CRS95
(c) τ̂ = 11.38 from CRS99 (d) τ̂ = 6 from New Zealand
(e) CTM-based net survival (f) Relative survival
Figure E.12: ST (t|k) and SO(t|k) of lung, trachea, and bronchus cancer data and general
population in Taiwan, where k is cure time estimated from CTM, CRS95, CRS99, and New
Zealand (2006). (E.12a-E.12d). Model-based net survival and relative survival (E.12e, E.12f),
horizontal and vertical dashed lines represent locations of CTM-estimated cure time and cure
rate, respectively.
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(a) τ̂ = 6 from CTM (b) τ̂ = 12.86 from CRS95
(c) τ̂ = 12.86 from CRS99 (d) τ̂ = 20 from New Zealand
(e) CTM-based net survival (f) Relative survival
Figure E.13: ST (t|k) and SO(t|k) of non-Hodgkin lymphoma data and general population in
Taiwan, where k is cure time estimated from CTM, CRS95, CRS99, and New Zealand (2006).
(E.13a-E.13d). Model-based net survival and relative survival (E.13e, E.13f), horizontal and
vertical dashed lines represent locations of CTM-estimated cure time and cure rate, respectively.
Note that in E.13d there is no ST (t|k) and SO(t|k) since the follow-up time (12.96 years) is
smaller than the cure time (20 years).
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(a) τ̂ = 7.33 from CTM (b) τ̂ = 8.02 from CRS95
(c) τ̂ = 8.45 from CRS99 (d) τ̂ = 6 from New Zealand
(e) CTM-based net survival (f) Relative survival
Figure E.14: ST (t|k) and SO(t|k) of oesophagus cancer data and general population in Taiwan,
where k is cure time estimated from CTM, CRS95, CRS99, and New Zealand (2006). (E.14a-
E.14d). Model-based net survival and relative survival (E.14e, E.14f), horizontal and vertical
dashed lines represent locations of CTM-estimated cure time and cure rate, respectively.
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(a) τ̂ = 7.51 from CTM (b) τ̂ = 6.34 from CRS95
(c) τ̂ = 7.50 from CRS99 (d) τ̂ = 10 from New Zealand
(e) CTM-based net survival (f) Relative survival
Figure E.15: ST (t|k) and SO(t|k) of ovary cancer data and general population in Taiwan, where
k is cure time estimated from CTM, CRS95, CRS99, and New Zealand (2006). (E.15a-E.15d).
Model-based net survival and relative survival (E.15e, E.15f), horizontal and vertical dashed
lines represent locations of CTM-estimated cure time and cure rate, respectively. Note that in
E.15d there is no ST (t|k) and SO(t|k) since the follow-up time (7.99 years) is smaller than the
cure time (10 years).
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(a) τ̂ = 3.52 from CTM (b) τ̂ = 6.39 from CRS95
(c) τ̂ = 6.39 from CRS99 (d) τ̂ = 5 from New Zealand
(e) CTM-based net survival (f) Relative survival
Figure E.16: ST (t|k) and SO(t|k) of pancreas cancer data and general population in Taiwan,
where k is cure time estimated from CTM, CRS95, CRS99, and New Zealand (2006). (E.16a-
E.16d). Model-based net survival and relative survival (E.16e, E.16f), horizontal and vertical
dashed lines represent locations of CTM-estimated cure time and cure rate, respectively.
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(a) τ̂ = 7.31 from CTM (b) τ̂ = 2.87 from CRS95
(c) τ̂ = 5.38 from CRS99 (d) τ̂ = 20 from New Zealand
(e) CTM-based net survival (f) Relative survival
Figure E.17: ST (t|k) and SO(t|k) of prostate cancer data and general population in Taiwan,
where k is cure time estimated from CTM, CRS95, CRS99, and New Zealand (2006). (E.17a-
E.17d). Model-based net survival and relative survival (E.17e, E.17f), horizontal and vertical
dashed lines represent locations of CTM-estimated cure time and cure rate, respectively. Note
that in E.17d there is no ST (t|k) and SO(t|k) since the follow-up time (9 years) is smaller than
the cure time (20 years).
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(a) τ̂ = 5.36 from CTM (b) τ̂ = 5.79 from CRS95
(c) τ̂ = 8.33 from CRS99 (d) τ̂ = 6 from New Zealand
(e) CTM-based net survival (f) Relative survival
Figure E.18: ST (t|k) and SO(t|k) of stomach cancer data and general population in Taiwan,
where k is cure time estimated from CTM, CRS95, CRS99, and New Zealand (2006). (E.18a-
E.18d). Model-based net survival and relative survival (E.18e, E.18f), horizontal and vertical
dashed lines represent locations of CTM-estimated cure time and cure rate, respectively.
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(a) τ̂ = 4.02 from CTM (b) τ̂ = 4.02 from CRS95
(c) τ̂ = 4.02 from CRS99 (d) τ̂ = 3 from New Zealand
(e) CTM-based net survival (f) Relative survival
Figure E.19: ST (t|k) and SO(t|k) of testis cancer data and general population in Taiwan, where
k is cure time estimated from CTM, CRS95, CRS99, and New Zealand (2006). (E.19a-E.19d).
Model-based net survival and relative survival (E.19e, E.19f), horizontal and vertical dashed
lines represent locations of CTM-estimated cure time and cure rate, respectively.
75
(a) τ̂ = 6.31 from CTM (b) τ̂ = 1.46 from CRS95
(c) τ̂ = 6.31 from CRS99 (d) τ̂ = 5 from New Zealand
(e) CTM-based net survival (f) Relative survival
Figure E.20: ST (t|k) and SO(t|k) of thyroid cancer data and general population in Taiwan,
where k is cure time estimated from CTM, CRS95, CRS99, and New Zealand (2006). (E.20a-
E.20d). Model-based net survival and relative survival (E.20e, E.20f), horizontal and vertical
dashed lines represent locations of CTM-estimated cure time and cure rate, respectively.
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(a) τ̂ = 5.76 from CTM (b) τ̂ = 2.77 from CRS95
(c) τ̂ = 5.37 from CRS99 (d) τ̂ = 6 from New Zealand
(e) CTM-based net survival (f) Relative survival
Figure E.21: ST (t|k) and SO(t|k) of uterus cancer data and general population in Taiwan, where
k is cure time estimated from CTM, CRS95, CRS99, and New Zealand (2006). (E.21a-E.21d).
Model-based net survival and relative survival (E.21e, E.21f), horizontal and vertical dashed
lines represent locations of CTM-estimated cure time and cure rate, respectively.
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